LDHA and GO dual inhibitor

in vitro activity and X-ray vs. both targets

from SBDD of LDHA and GO inhibitors

ACS Med. Chem. Lett., May 20, 2021

Chinook Therapeutics, Seattle, WA

Compound-7-(GO_LDHA)

The Chinook LDHA/GO dual inhibitor, compound 7, targets two clinically validated targets for hyperoxaluria, a rare genetic disorder that results in oxalate overproduction and sometimes kidney failure. GO is encoded…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: